Skip to main content

Advertisement

SpringerLink
Log in

Deregulated Expression of miR-483-3p Serves as a Diagnostic Biomarker in Severe Pneumonia Children with Respiratory Failure and Its Predictive Value for the Clinical Outcome of Patients

  • Original Paper
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

Severe pneumonia in children is a group of inflammatory diseases of respiratory tract caused by pathogenic microorganisms. Increasing evidence suggested the crucial effects of microRNA on inflammatory diseases. This study aimed to reveal the expression and role of miR-483-3p in the serum of children with severe pneumonia, and to explore the effect of miR-483-3p on the biological function of lipopolysaccharide (LPS)-induced MRC-5 cells. MRC-5 cells were disposed with LPS to construct an in vitro pneumonia cell model. The relative expression level of miR-483-3p was measured by qRT-PCR. ROC curve was used to evaluate the diagnostic value of miR-483-3p in severe pneumonia. The Kaplan–Meier curve was performed to test the characteristics of survival distribution of different miRNA classifications. Cell viability and apoptosis were performed by CCK-8 assay and flow cytometry. IL-1β, TNF-α, and IL-6 were detected by ELISA. Luciferase reporter gene assay and western blot analysis were performed to detect the interaction between miR-483-3p and IGF-1. The expression of serum miR-483-3p in severe pneumonia patients was higher than in controls. The AUC value of the ROC curve was 0.919, indicating that miR-483-3p had diagnostic value for severe pneumonia. The survival curve showed that patients with high expression of miR-483-3p had higher mortality. Cell viability and apoptosis assay showed that overexpression of miR-483-3p suppressed cell proliferation and promoted apoptosis. And upregulation of miR-483-3p promoted generation of inflammatory cytokines. Luciferase report gene assay and western blot assay both illustrated that IGF-1 might be the target gene of miR-483-3p. Serum miR-483-3p can be used as a biomarker for the diagnosis of severe pneumonia. High expression of miR-483-3p promoted the development of severe pneumonia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Waites, K. B. (2003). New concepts of Mycoplasma pneumoniae infections in children. Pediatric Pulmonology, 36, 267–278.

    Article  Google Scholar 

  2. Levine, O. S., O’Brien, K. L., Deloria-Knoll, M., Murdoch, D. R., Feikin, D. R., DeLuca, A. N., et al. (2012). The pneumonia etiology research for child health project: A 21st century childhood pneumonia etiology study. Clinical Infectious Diseases, 54(Suppl 2), S93-101.

    Article  Google Scholar 

  3. Chen, Z. R., Zhang, G. B., Wang, Y. Q., Yan, Y. D., Zhou, W. F., Zhu, C. H., et al. (2013). Soluble B7–H3 elevations in hospitalized children with Mycoplasma pneumoniae pneumonia. Diagnostic Microbiology and Infectious Disease, 77, 362–366.

    Article  CAS  Google Scholar 

  4. Ebrahimi, A., & Sadroddiny, E. (2015). MicroRNAs in lung diseases: Recent findings and their pathophysiological implications. Pulmonary Pharmacology & Therapeutics, 34, 55–63.

    Article  CAS  Google Scholar 

  5. Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116, 281–297.

    Article  CAS  Google Scholar 

  6. Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nature Reviews Drug Discovery, 16, 203–222.

    Article  CAS  Google Scholar 

  7. Jin, F., Hu, H., Xu, M., Zhan, S., Wang, Y., Zhang, H., et al. (2018). Serum microRNA profiles serve as novel biomarkers for autoimmune diseases. Frontiers in Immunology, 9, 2381.

    Article  Google Scholar 

  8. Kumar, S., Vijayan, M., Bhatti, J. S., & Reddy, P. H. (2017). MicroRNAs as peripheral biomarkers in aging and age-related diseases. Progress in Molecular Biology and Translational Science, 146, 47–94.

    Article  CAS  Google Scholar 

  9. Wojciechowska, A., Braniewska, A., & Kozar-Kaminska, K. (2017). MicroRNA in cardiovascular biology and disease. Advances in Clinical and Experimental Medicine, 26, 865–874.

    Article  Google Scholar 

  10. Abd-El-Fattah, A. A., Sadik, N. A., Shaker, O. G., & Aboulftouh, M. L. (2013). Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochemistry and Biophysics, 67, 875–884.

    Article  CAS  Google Scholar 

  11. Fei, S., Cao, L., & Pan, L. (2018). microRNA3941 targets IGF2 to control LPSinduced acute pneumonia in A549 cells. Molecular Medicine Reports, 17, 4019–4026.

    CAS  PubMed  Google Scholar 

  12. Ying, H., Kang, Y., Zhang, H., Zhao, D., Xia, J., Lu, Z., et al. (2015). MiR-127 modulates macrophage polarization and promotes lung inflammation and injury by activating the JNK pathway. The Journal of Immunology, 194, 1239–1251.

    Article  CAS  Google Scholar 

  13. Fu, H., Tie, Y., Xu, C., Zhang, Z., Zhu, J., Shi, Y., et al. (2005). Identification of human fetal liver miRNAs by a novel method. FEBS Letters, 579, 3849–3854.

    Article  CAS  Google Scholar 

  14. Liu, P., Yang, X., Zhang, H., Pu, J., & Wei, K. (2018). Analysis of change in microRNA expression profiles of lung cancer A549 cells treated with radix tetrastigma hemsleyani flavonoids. Oncotargets and Therapy, 11, 4283–4300.

    Article  Google Scholar 

  15. Huang, S., Feng, C., Zhai, Y. Z., Zhou, X., Li, B., Wang, L. L., et al. (2017). Identification of miRNA biomarkers of pneumonia using RNA-sequencing and bioinformatics analysis. Experimental and Therapeutic Medicine, 13, 1235–1244.

    Article  CAS  Google Scholar 

  16. Dean, P., & Florin, T. A. (2018). Factors associated with pneumonia severity in children: A systematic review. Journal of Pediatric Infectious Diseases Society, 7, 323–334.

    Google Scholar 

  17. Ruuskanen, O., Lahti, E., Jennings, L. C., & Murdoch, D. R. (2011). Viral pneumonia. Lancet, 377, 1264–1275.

    Article  Google Scholar 

  18. Boyd, K. (2017). Back to the basics: Community-acquired pneumonia in children. Pediatric Annals, 46, e257–e261.

    Article  Google Scholar 

  19. le Roux, D. M., & Zar, H. J. (2017). Community-acquired pneumonia in children—A changing spectrum of disease. Pediatric Radiology, 47, 1392–1398.

    Article  Google Scholar 

  20. Hirsch, A. W., Monuteaux, M. C., Fruchtman, G., Bachur, R. G., & Neuman, M. I. (2016). Characteristics of children hospitalized with aspiration pneumonia. Hospital Pediatrics, 6, 659–666.

    Article  Google Scholar 

  21. Polikepahad, S., Knight, J. M., Naghavi, A. O., Oplt, T., Creighton, C. J., Shaw, C., et al. (2010). Proinflammatory role for let-7 microRNAS in experimental asthma. Journal of Biological Chemistry, 285, 30139–30149.

    Article  Google Scholar 

  22. Maemura, T., Fukuyama, S., & Kawaoka, Y. (2020). High levels of miR-483-3p are present in serum exosomes upon infection of mice with highly pathogenic avian influenza virus. Frontiers in Microbiology, 11, 144.

    Article  Google Scholar 

  23. Stiles, A. D., & D’Ercole, A. J. (1990). The insulin-like growth factors and the lung. American Journal of Respiratory Cell and Molecular Biology, 3, 93–100.

    Article  CAS  Google Scholar 

  24. Trueba-Saiz, A., Fernandez, A. M., Nishijima, T., Mecha, M., Santi, A., Munive, V., et al. (2017). Circulating insulin-like growth factor I regulates its receptor in the brain of male mice. Endocrinology, 158, 349–355.

    CAS  PubMed  Google Scholar 

  25. Oherle, K., Acker, E., Bonfield, M., Wang, T., Gray, J., Lang, I., et al. (2020). Insulin-like growth factor 1 supports a pulmonary niche that promotes type 3 innate lymphoid cell development in newborn lungs. Immunity, 52, 275–294.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Juan Zhou and Jianming Lin contributed equally.

Authors and Affiliations

  1. Department of Pediatrics Medicine, Yidu Central Hospital of Weifang, Weifang, 262500, Shandong, China

    Juan Zhou & Jianming Lin

  2. Department of Geriatric Health, Yidu Central Hospital of Weifang, Weifang, 262500, Shandong, China

    Yanping Zhao

  3. Department of Neurology, Yidu Central Hospital of Weifang, 4138 Linglongshan Road, Qingzhou, Weifang, 262500, Shandong, China

    Xibo Sun

Authors
  1. Juan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianming Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanping Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xibo Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xibo Sun.

Ethics declarations

Conflict of interest

The authors declared that they have no conflict of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, J., Lin, J., Zhao, Y. et al. Deregulated Expression of miR-483-3p Serves as a Diagnostic Biomarker in Severe Pneumonia Children with Respiratory Failure and Its Predictive Value for the Clinical Outcome of Patients. Mol Biotechnol 64, 311–319 (2022). https://doi.org/10.1007/s12033-021-00415-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12033-021-00415-7

Keywords

Search

Navigation